Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia

[1]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[2]  T. A. Jacobson,et al.  Statin-induced myopathy: a review and update , 2011, Expert opinion on drug safety.

[3]  B. Paulweber,et al.  Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe , 2010, Current opinion in lipidology.

[4]  C. Tsioufis,et al.  Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. , 2010, International journal of cardiology.

[5]  V. Gahtan,et al.  Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease , 2010, Vascular and endovascular surgery.

[6]  G. Norata,et al.  Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. , 2009, Atherosclerosis.

[7]  T. Meinertz,et al.  Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. , 2009, Atherosclerosis.

[8]  J. Liao,et al.  Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation , 2009, Circulation.

[9]  F. Visseren,et al.  The Effects of Low-Dose Simvastatin and Ezetimibe Compared to High-Dose Simvastatin Alone on Post-Fat Load Endothelial Function in Patients With Metabolic Syndrome: A Randomized Double-Blind Crossover Trial , 2008, Journal of cardiovascular pharmacology.

[10]  L. Rydén,et al.  Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. , 2008, European heart journal.

[11]  G. Thompson.  Recommendations for the use of LDL apheresis. , 2008, Atherosclerosis.

[12]  J. Armitage,et al.  The safety of statins in clinical practice , 2007, The Lancet.

[13]  I. Wilkinson,et al.  Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. , 2007, Journal of the American College of Cardiology.

[14]  K. Node,et al.  Statin Therapy for Vascular Failure , 2007, Cardiovascular Drugs and Therapy.

[15]  S. Efrati,et al.  The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers , 2007, European Journal of Clinical Pharmacology.

[16]  C. Heeschen,et al.  Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. , 2006, European heart journal.

[17]  Zhihong Yang,et al.  Recent advances in understanding endothelial dysfunction in atherosclerosis. , 2006, Clinical medicine & research.

[18]  M. Spiecker,et al.  Endothelial Function in the Forearm Circulation of Patients with the Metabolic Syndrome – Effect of Different Lipid-Lowering Regimens , 2005, Cardiology.

[19]  W. März,et al.  Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans , 2005, Circulation.

[20]  J. Davignon.  Beneficial Cardiovascular Pleiotropic Effects of Statins , 2004, Circulation.

[21]  A. Catapano,et al.  Lipoprotein remnants and endothelial dysfunction in the postprandial phase. , 2004, The Journal of clinical endocrinology and metabolism.

[22]  P. Libby,et al.  Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? , 2004, Circulation.

[23]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[24]  Ernesto L. Schiffrin,et al.  Endothelial dysfunction. , 2004, Journal of the American Society of Nephrology : JASN.

[25]  M. Nishimura,et al.  Improvement of endothelium‐dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia , 2004, Journal of clinical apheresis.

[26]  E. Schiffrin,et al.  Endothelial dysfunction. , 2004, Journal of the American Society of Nephrology : JASN.

[27]  W. Hofmann,et al.  HMG-CoA Reductase Inhibitors Reduce Senescence and Increase Proliferation of Endothelial Progenitor Cells via Regulation of Cell Cycle Regulatory Genes , 2003, Circulation research.

[28]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[29]  大森 久子.  Direct in vivo evidence of a vascular statin : a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects , 2003 .

[30]  Meehyung Cho,et al.  Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. , 2002, The American journal of cardiology.

[31]  Eric K. Gupta,et al.  Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. , 2002, Heart disease.

[32]  O. Pachinger,et al.  Short‐ and long‐term changes of flow‐mediated vasodilation in patients under statin therapy , 2002, Clinical cardiology.

[33]  U. Laufs,et al.  Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[34]  J. Isner,et al.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. , 2001, The Journal of clinical investigation.

[35]  A M Zeiher,et al.  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. , 2001, The Journal of clinical investigation.

[36]  C. Dessy,et al.  Hydroxy-Methylglutaryl–Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance , 2001, Circulation.

[37]  Wulf Palinsk.  New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering , 2001 .

[38]  W. Palinski,et al.  New evidence for beneficial effects of statins unrelated to lipid lowering. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[39]  M. Hecker,et al.  Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[40]  J. Viikari,et al.  HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. , 1999, Atherosclerosis.

[41]  J. Tardif,et al.  Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. , 1999, Circulation.

[42]  M. Essig,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. , 1998, Circulation research.

[43]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[44]  J. Tardif,et al.  Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes , 1998 .

[45]  U. Laufs,et al.  Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase* , 1997, The Journal of Biological Chemistry.

[46]  C. Jones,et al.  Non-invasive assessment of endothelial function. , 1997, Heart.

[47]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[48]  T. Imaizumi,et al.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.

[49]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[50]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[51]  A. Yeung,et al.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.

[52]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[53]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[54]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[55]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[56]  A. Quyyumi,et al.  The Role of Nitric Oxide in Endothelium‐Dependent Vasodilation of Hypercholesterolemic Patients , 1993, Circulation.

[57]  J. Loscalzo,et al.  Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. , 1990, The Journal of clinical investigation.

[58]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[59]  E. Nabel,et al.  Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. , 1989, Circulation.

[60]  S. Moncada,et al.  Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. , 1988, Biochemical pharmacology.

[61]  K. Bruckdorfer,et al.  Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta , 1987, Nature.